peppermint oil sanofi 0.2 ml gastro-resistant soft capsules
sanofi-aventis ireland limited t/a sanofi - peppermint oil - gastro-resistant capsule, soft - 0.2 millilitre(s) - other drugs for functional gastrointestinal disorders
amaryl 2 mg tablet 2.0mg milligram tablets
sanofi-aventis ireland limited t/a sanofi - glimepiride - tablets - 2.0mg milligram
amaryl 4 mg tablet 4.0mg milligram tablets
sanofi-aventis ireland limited t/a sanofi - glimepiride - tablets - 4.0mg milligram
nasacort 55 micrograms/dose, nasal spray, suspension
sanofi-aventis ireland limited t/a sanofi - triamcinolone acetonide - nasal spray, suspension - 55 microgram(s)/dose - corticosteroids; triamcinolone
opticrom allergy single dose 2% w/v eye drops, solution
sanofi-aventis ireland limited t/a sanofi - sodium cromoglicate - eye drops, solution - 2 percent weight/volume - other antiallergics; cromoglicic acid
amaryl 1 mg tablet
sanofi-aventis ireland limited t/a sanofi - glimepiride - tablet - 1.0 milligram(s) - sulfonamides, urea derivatives; glimepiride
amaryl 3 mg tablet
sanofi-aventis ireland limited t/a sanofi - glimepiride - tablet - 3 milligram(s) - sulfonamides, urea derivatives; glimepiride
acomplia
sanofi-aventis - rimonabant - obesity - antiobesity preparations, excl. diet products - as an adjunct to diet and exercise for the treatment of obese patients (bmi 30 kg/m2), or overweight patients (bmi 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5.1).
insulin human winthrop
sanofi-aventis deutschland gmbh - insulin human - diabetes mellitus - drugs used in diabetes - diabetes mellitus where treatment with insulin is required. insulin human winthrop rapid is also suitable for the treatment of hyperglycaemic coma and ketoacidosis, as well as for achieving pre-, intra- and postoperative stabilisation in patients with diabetes mellitus.
zimulti
sanofi-aventis - rimonabant - obesity - antiobesity preparations, excl. diet products - as an adjunct to diet and exercise for the treatment of obese patients (bmi 30 kg/m2), or overweight patients (bmi 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5.1).